Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251

Diabetes Care. 2022 Oct 1;45(10):e151-e152. doi: 10.2337/dci22-0025.

Gaetano Santulli^{1

2

3}, Salvatore Frullone⁴, Maria Morgante⁴, Gaetano Macina⁴, Antonella Pansini⁴, Jessica Gambardella^{1

3}, Angela Lombardi¹, Pasquale Mone^{1

2

5}

¹ Department of Medicine, Einstein-Sinai Diabetes Research Center (FIDAM), The Fleischer Institute for Diabetes and Metabolism (ES-DRC), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY.
² Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY.
³ International Translational Research and Medical Education Consortium (ITME), "Federico II" University, Naples, Italy.
⁴ Azienda Sanitaria Locale Avellino, Avellino, Italy.
⁵ Department of Preventive Medicine, Campania University, Naples, Italy.

No abstract available

Publication types